What's Happening?
The use of GLP-1 drugs, such as Ozempic and Wegovy, for weight loss in the United States has nearly quadrupled over the past two years. A recent Gallup survey indicates that 11% of U.S. adults are currently using these medications, up from 3% in 2024.
The increased use of GLP-1 drugs coincides with a decline in national obesity rates, which have fallen from a peak of 39.9% in 2022 to 36.4% in 2026. The market for GLP-1 drugs has expanded with new entrants like Eli Lilly's Zepbound and Mounjaro, further driving the popularity of these treatments.
Why It's Important?
The surge in GLP-1 drug use represents a significant shift in the approach to managing obesity in the U.S. The decline in obesity rates suggests that these medications are having a measurable impact on public health. The growing market for GLP-1 drugs highlights the demand for effective weight-loss solutions and the potential for pharmaceutical companies to capitalize on this trend. However, the increased use of these drugs also raises concerns about accessibility, affordability, and potential side effects, which could influence healthcare policies and insurance coverage decisions.
What's Next?
As the demand for GLP-1 drugs continues to rise, pharmaceutical companies may focus on developing more convenient and potent versions to capture a larger market share. The introduction of oral GLP-1 options, such as Eli Lilly's Foundayo, could further expand the market. Additionally, ongoing research into new applications for GLP-1 drugs, beyond weight loss and diabetes, could lead to broader uses and increased adoption. Policymakers and healthcare providers will need to address issues related to cost, insurance coverage, and patient education to ensure equitable access to these treatments.
